Experience with methotrexate in a patient with calcium pyrophosphate crystal deposition disease | Zendy

E. V. Ilyinykh | Zendy; М. С. Елисеев | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Experience with methotrexate in a patient with calcium pyrophosphate crystal deposition disease

Author(s) -

E. V. Ilyinykh,

М. С. Елисеев

Publication year - 2019

Publication title -

modern rheumatology journal

Language(s) - English

Resource type - Journals

eISSN - 2310-158X

pISSN - 1996-7012

DOI - 10.14412/1996-7012-2019-4-96-98

Subject(s) - medicine , hydroxychloroquine , calcium pyrophosphate , methotrexate , colchicine , pyrophosphate , nonsteroidal , calcium , drug , chondrocalcinosis , deposition (geology) , crystal (programming language) , pharmacology , disease , biochemistry , pathology , covid-19 , enzyme , osteoarthritis , chemistry , alternative medicine , paleontology , sediment , computer science , infectious disease (medical specialty) , programming language , biology

The paper discusses the results of using methotrexate (MTX) in real clinical practice in a patient with calcium pyrophosphate crystal deposition resistant to traditional anti-inflammatory drugs (colchicine, nonsteroidal anti-inflammatory drugs, and hydroxychloroquine) It demonstrates the efficiency and possibility of safely using MTX at a dose of 20 mg/week during a year.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research